How I treat relapsed and/or refractory multiple myeloma
The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...
| Published in: | Hematology Reports |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8955 |